Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

The Food and Drug Administration on Friday approved Eli Lilly’s anti-obesity drug Zepbound as the first prescription medicine ...

Eli Lilly’s popular anti-obesity drug Zepbound could get a sales boost after the U.S. Medicare program decided to pay for its use to treat sleep apnea. The Centers f ...

The U.S. Food and Drug Administration (FDA) has granted approval for Zepbound, a weight-loss medication, to treat moderate to severe obstructive sleep apnea (OSA) in individuals with obesity.

For Floridians, 2024 was a year of weight loss and emerging revelations about anti-obesity medications.

Immuno-oncology (IO) drugs used to treat cancer boost the immune response to a disease. Immunotherapy treatment uses a person’s immune system to fight cancer with monoclonal antibodies ...

Eli Lilly's obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, ...

The Food and Drug Administration on Friday approved Eli Lilly’s anti-obesity drug Zepbound as the first prescription medicine for obstructive sleep apnea, marking a major shift in the treatment ...

A 2024 study in the American Journal of Managed Care found that patients’ health care costs declined by $7,502 after they began treatment with the anti-obesity drug semaglutide. Importantly ...

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for ... [+] health insurers, employers and government health programs who cover it in 2025.